Patients with high-risk or intermediate-risk disease may benefit from allogeneic stem cell transplantation as a potentially “curative approach.”
Guenther Koehne, MD
Advertisement
Articles by Guenther Koehne, MD
Adverse effects of novel immunotherapies appear controllable compared with chemotherapy in hematologic malignancies, according to Guenther Koehne, MD.
Advertisement
Latest Updated Articles
Is a Functional Cure Possible in Multiple Myeloma Therapy?March 25th 2026
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
2
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
3
FDA ODAC Votes Yes to Capivasertib for PTEN-Deficient Metastatic HSPC
4
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
5